Company: ABBV
Filing Date: 2025-02-05
Form Type: 8-K
Source: 0001104659-25-009673
Chunk: 0

Company: AbbVie Inc.
Filing Date: 2025-02-05
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01      Other    

Revolving
Credit Agreement

On January
30, 2025 (the “ Effective Date”), AbbVie Inc. (“ AbbVie”) entered into a revolving credit agreement (the “ Revolving
Credit Agreement”) among AbbVie, as borrower, the lenders and other parties party thereto and JPMorgan Chase Bank, N. A., as administrative
agent. The Revolving Credit Agreement establishes an unsecured revolving credit facility of up to $3.0 billion which matures on January
30, 2030. This facility enables AbbVie to borrow funds on an unsecured basis at variable interest
rates and contains various covenants. AbbVie had no borrowings outstanding under the Revolving Credit Agreement on the Effective Date.
AbbVie’s existing $5.0 billion revolver maturing in March 2028 remains in effect, such that as of the Effective Date AbbVie has
access to revolving credit facilities totaling $8.0 billion in the aggregate.

SIGNATURE

Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                        ABBVIE INC.                                               
                        By:              /s/                                      
  Date:                 Name:            Scott                                    
                        Title:           Executive